CPT code 0615U identifies a Proprietary Laboratory Analyses (PLA) test: the iDart™ Lyme IgM ImmunoBlot Kit from ID–FISH Technology Inc., an immunoassay that detects IgM antibodies to 26 recombinant Borrelia burgdorferi protein groups for evaluation of Lyme disease. PLA codes are single‑source codes tied to a specific manufacturer or laboratory, making 0615U important for accurate tracking, billing, and utilization monitoring of this proprietary Lyme assay nationwide.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage considerations, national benchmarking context, and clinical application of the assay in Lyme disease evaluation. Readers will find: an overview of the code’s clinical purpose and service settings; expected billing and coding context for laboratory services; comparison of payer coverage presence and potential reimbursement patterns; and implications for laboratory operations and reporting when using a PLA code.

This summary is intended for billing managers, laboratory directors, and policy analysts seeking concise national context on CPT code 0615U, its clinical role in Lyme disease serology, and the administrative considerations tied to a proprietary laboratory test.